261 related articles for article (PubMed ID: 32033147)
1. Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study.
Vianello A; Salton F; Molena B; Turato C; Graziani ML; Braccioni F; Frassani V; Sella D; Pretto P; Paladini L; Sukthi A; Confalonieri M
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32033147
[TBL] [Abstract][Full Text] [Related]
2. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis.
Huh JY; Lee JH; Song JW
Front Pharmacol; 2023; 14():1301923. PubMed ID: 38192410
[No Abstract] [Full Text] [Related]
4. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
Ikeda S; Sekine A; Baba T; Kato T; Katano T; Tabata E; Shintani R; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
Medicine (Baltimore); 2022 Jun; 101(22):e29232. PubMed ID: 35665728
[TBL] [Abstract][Full Text] [Related]
7. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
[TBL] [Abstract][Full Text] [Related]
8. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
9. Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience.
Levra S; Guida G; Sprio AE; Crosa F; Ghio PC; Bertolini F; Carriero V; Albera C; Ricciardolo FLM
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551989
[TBL] [Abstract][Full Text] [Related]
10. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.
Toellner H; Hughes G; Beswick W; Crooks MG; Donaldson C; Forrest I; Hart SP; Leonard C; Major M; Simpson AJ; Chaudhuri N
Clin Transl Med; 2017 Nov; 6(1):41. PubMed ID: 29101500
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
[TBL] [Abstract][Full Text] [Related]
13. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
[TBL] [Abstract][Full Text] [Related]
14. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Bonella F; Kreuter M; Hagmeyer L; Neurohr C; Keller C; Kohlhaeufl MJ; Müller-Quernheim J; Milger K; Prasse A;
Respiration; 2016; 92(2):98-106. PubMed ID: 27544537
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
Cilli A; Uzer F; Sevinç C; Coşkun F; Ursavaş A; Öner Ş; Kose F
Pulm Pharmacol Ther; 2021 Dec; 71():102099. PubMed ID: 34793978
[TBL] [Abstract][Full Text] [Related]
16. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
17. Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis.
Santoleri F; Auriemma L; Spacone A; Marinari S; Esposito F; De Vita F; Petragnani G; Di Fabio C; Di Fabio L; Costantini A
J Pharm Pract; 2022 Dec; 35(6):853-858. PubMed ID: 33878986
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review.
Man RK; Gogikar A; Nanda A; Janga LSN; Sambe HG; Yasir M; Ramphall S
Cureus; 2024 Feb; 16(2):e54268. PubMed ID: 38500898
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S; Miyahara N; Taniguchi A; Oda N; Itano J; Higo H; Hara N; Watanabe H; Kano H; Suwaki T; Fuchimoto Y; Kajimoto K; Ichikawa H; Kudo K; Shibayama T; Tanimoto Y; Kuyama S; Kanehiro A; Maeda Y; Kiura K;
PLoS One; 2020; 15(8):e0236935. PubMed ID: 32853277
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
